Work in progress: potential oral and intravenous paramagnetic NMR contrast agents.
The potential use of paramagnetic compounds as nuclear magnetic resonance (NMR) contrast agents was examined in vitro. The T1 relaxation times for serial dilutions of Cu2+, Cr3+, Fe3+, and Mn2+ ions in saline, gadolinium oxalate (a potential oral contrast agent) in suspension, and chromium EDTA (a potential intravenous contrast agent) in solution were determined. The effect on T1 of increasing the concentration of oxygen in solution was also examined. The relative magnitude of the decrease in T1 was, as expected, proportional to both the concentration of the paramagnetic substance and its effective magnetic moment. Thus NMR has the potential to detect differences in tissue oxygenation. By incorporating paramagnetic metal ions into insoluble compounds or stable complexes, toxicity can be dramatically reduced while maintaining a significant paramagnetic effect. Highly insoluble paramagnetic compounds or stable paramagnetic ion complexes can thus be utilized as effective NMR contrast agents with significantly diminished toxicity.
D000284:Administration, Oral; D002614:Chelating Agents / Q000008:administration & dosage; D002857:Chromium / Q000008:administration & dosage; D003287:Contrast Media / Q000008:administration & dosage*; D003300:Copper / Q000008:administration & dosage; D005682:Gadolinium / Q000008:administration & dosage; D007275:Injections, Intravenous; D007477:Ions; D007501:Iron / Q000008:administration & dosage; D009682:Magnetic Resonance Spectroscopy; D008345:Manganese / Q000008:administration & dosage
D002614:Chelating Agents; D003287:Contrast Media; D007477:Ions; D002857:Chromium; D008345:Manganese; D003300:Copper; D005682:Gadolinium; D007501:Iron